Alveolar Soft Part Sarcoma with Unusual Cardiac Metastasis: A Case Report and Review of the Literature

Abhinav Tiwari,1 Bhavana Siddegowda Bangalore,2 Himani Sharma,1 Zaid Ammari,1 Mohammad S. Khan,1 Zubair Khan,1 and Hermann Simo1

1Department of Internal Medicine, University of Toledo Medical Center, 3000 Arlington Avenue, MS 1150, Toledo, OH 43614, USA
2Department of Cardiology, University of Toledo Medical Center, 3000 Arlington Avenue, MS 1150, Toledo, OH 43614, USA

Correspondence should be addressed to Abhinav Tiwari; Abhinav.tiwari@utoledo.edu

Received 3 March 2017; Accepted 4 July 2017; Published 6 August 2017

1. Introduction

Alveolar soft part sarcoma (ASPS) is a rare soft tissue neoplasm that accounts for less than 1% of all soft tissue sarcomas [1] and affects individuals between 15 and 35 years of age primarily, with a slight female preponderance [2]. In adults, the most common site is the deep soft tissues in the thigh or buttock. However, it is known to occur in organs such as lungs, breasts, stomach, female genital organs, and bones [3, 4]. It is a malignant and highly vascular tumor arising most commonly in the musculature of the lower extremities, with metastasis primarily to the lungs, bones, and brain. Cardiac metastasis is very rare and only 5 cases have been reported in the literature so far. We report a case of a young woman with a history of surgically resected alveolar soft part sarcoma of left thigh who presented with persistent dry cough and was found to have a cardiac mass, which on biopsy proved to be alveolar soft part sarcoma.

2. Case Presentation

A 31-year-old female with a history of ASPS in the left thigh treated with neoadjuvant radiation followed by radical excision of the mass was seen one year later for dry cough of 1-month duration. She denied any chest pain, fever, or shortness of breath. Cough was refractory to over-the-counter cough suppressants. She had a normal chest X-ray and was even treated with a 5-day course of azithromycin by the primary care physician. On exam, she had normal lung sounds while cardiac examination revealed a 2/6 holosystolic murmur over the left heart border. Due to persistent nature of this cough, a computerized tomography (CT) scan of the chest was performed that revealed a large (4.5 cm) right ventricular (RV) mass and pericardial effusion (Figure 1). She was referred to cardiology clinic, where a transthoracic echocardiogram showed a large right ventricular mass about 5 cm in size. She was then taken for right heart catheterization (RHC) to obtain a tissue specimen. Preoperative 2D echocardiogram confirmed a large 5.5 × 7.5 cm mass that was intimately associated with right ventricular free wall encroaching upon the AV groove and interfering with the tricuspid valve (TV) mechanism (Figure 2). On RHC, the pressure findings were consistent with the physiology of TV stenosis caused by obstructing mass. Pulmonary capillary wedge pressure was 5 mm Hg, RV pressure was 25/3 mm Hg, the right atrial pressure was 14 mm Hg, and pulmonary artery pressure was 15/6 mm Hg. Pericardiocentesis was performed and 420 mL of hemorrhagic pericardial fluid was drained. Intraoperative frozen section of the RV mass was consistent with ASPS (Figure 3). Transcription factor E3 (TFE-3) immunostain revealed strong and diffuse nuclear immunoreactivity of tumor cells. The patient was transferred to a specialized
Figure 1: Computerized tomography of chest with contrast showing a large right ventricular mass (arrow) and pericardial effusion.

Figure 2: 2D echocardiogram of the heart in apical four chamber view showing a right ventricular mass (arrow) arising from the free wall.

cardiothoracic surgical center for intervention, where partial resection of the cardiac mass was performed.

3. Discussion

ASPS is a very uncommon soft tissue malignancy that was originally described by Smetana and Scott Jr. in 1951 as a malignant tumor of the nonchromaffin paraganglia [7]. Christopherson et al. later described it under the name of “alveolar soft part sarcoma” in 1952 [8]. ASPS accounts for <1% of soft tissue sarcoma and typically occurs in young adults with a female predominance [9, 10]. Although the most common site of the tumor is the musculature of the lower extremities [11], it is also known to occur in organs such as lungs, breasts, stomach, female genital organs, and bones [3, 4]. Typically, patients note a painless, slowly growing mass; however, some patients may present primarily with metastatic disease. It is an indolent and slowly growing tumor, but the overall 5-year survival is only 20% for nonresectable tumors [12, 13]. Despite being slow growing, it is a malignant and highly vascular tumor which metastasizes primarily to the lungs, bones, and brain, while cardiac metastasis is extremely rarely [5, 6]. Hematogenous dissemination which can occur long after resection of the primary tumor, even if there is no local recurrence [14–16].

To the best of our knowledge, there have been five cases of cardiac metastases reported so far. Chen et al. reported a case of ASPS of left arm which 3 years later metastasized to heart, brain, lung, and spleen. The patient succumbed to cachexia and biopsy or resection of the cardiac tumor was not performed [17]. Akiyama et al. reported a case of ASPS of the right thigh which was surgically removed and later metastasized to lungs, brain, intestines, and heart [18]. Strecker et al. reported a case of ASPS of right thigh with brain and later cardiac metastases, which could be excised partially [19]. Campbell et al. described a case of surgically resected ASPS of the right forearm which later spread to lungs, brain, and heart. Cardiac lesion was asymptomatic and was not resected [20]. Finally, Stark et al. described a case of left thigh ASPS which was surgically excised; 5 years later, the patient presented with signs of congestive heart failure and was diagnosed with cardiac metastasis of the tumor, which was surgically resected [21].

On imaging, the tumor is contrast enhancing due to its vascular nature [22]. ASPS tends to have high signal intensity on T1- to T2-weighted images on magnetic resonance imaging. On immunohistochemistry, ASPS is consistently positive for an antibody that detects carboxyl terminal of transcription factor 3 (TFE3) gene in the form of strong nuclear staining pattern [23, 24].

Although rarely curative, the cornerstone of treatment remains surgical excision of the primary and isolated metastases [12, 18]. Radiotherapy should be added as a supplemental procedure if there is partial resection of the tumor, positive surgical margin, or presence of symptomatic metastasis. There is a limited role of chemotherapy in treating solitary lesion. However, in the presence of multiple metastases of the lungs, brain, spleen, or heart, chemotherapy may be considered a treatment option. There is a limited success with anthracycline based chemotherapy regimens but the overall prognosis of ASPS is poor. Kummar et al. treated 43 metastatic, unresectable ASPS patients with cediranib (30 mg) once daily in 28-day cycles, and it was observed that cediranib has substantial single-agent activity, producing an...
An overall remission rate of 35% and a disease control rate of 84% at 24 weeks [12]. This trial is still ongoing.

In conclusion, this is a case of ASPS with rare event of cardiac metastasis. The patient with cardiac metastasis can remain asymptomatic or may have subtle symptoms such as cough or dyspnea. Such patients may also present with signs of frank congestive heart failure [21]. Therefore, in a patient with treated or untreated ASPS, it is imperative to consider cardiac metastasis in addition to more common pulmonary metastasis if the patient presents with respiratory or cardiac symptoms.

Conflicts of Interest

All authors have no financial conflicts of interest.

References

[1] H. E. Auerbach and J. J. Brooks, “Alveolar soft part sarcoma: a clinicopathologic and immunohistochemical study,” Cancer, vol. 60, no. 1, pp. 66–73, 1987.

[2] X. Bu and L. Bernstein, “A proposed explanation for female predominance in alveolar soft part sarcoma: noninactivation of X; autosome translocation fusion gene?” Cancer, vol. 103, no. 6, pp. 1245–1253, 2005.

[3] N. G. Ordóñez, “Alveolar soft part sarcoma: a review and update,” Advances in Anatomic Pathology, vol. 6, no. 3, pp. 125–139, 1999.

[4] D. B. Flieder, C. A. Moran, and S. Suster, “Primary alveolar soft-part sarcoma of the mediastinum: a clinicopathological and immunohistochemical study of two cases,” Histopathology, vol. 31, no. 5, pp. 469–473, 1997.

[5] P. H. Lieberman, M. F. Brennan, M. Kimmel, R. A. Erlandson, P. Garin-Chesa, and B. Y. Flehinger, “Alveolar soft-part sarcoma. A clinicopathologic study of half a century,” Cancer, vol. 63, no. 1, pp. 1–13, 1989.

[6] T. Onibq, Y. Hashimoto, Y. Fujinuma et al., “Hypervascular metastatic cardiac tumors: an unknown cause of mitral valve prolapse,” Internal Medicine, vol. 31, no. 1, pp. 78–81, 1992.

[7] H. F. Smetana and W. F. Scott Jr., “Malignant tumors of nonchromaffin paraganglia,” Military Surgeon, vol. 109, no. 4, pp. 330–349, 1951.

[8] W. M. Christopherson, F. W. Foote Jr., and F. W. Stewart, “Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis,” Cancer, vol. 5, no. 1, pp. 100–111, 1952.

[9] L. L. Zhang, Q. Tang, Z. Wang, and X. S. Zhang, “Alveolar soft part sarcoma of the uterine cervix with pelvic lymph node metastasis: case report and literature review,” International Journal of Clinical and Experimental Pathology, vol. 5, no. 7, pp. 715–719, 2012.

[10] A. Yavuz, C. Göya, A. Bora, and M. Beyazal, “Primary alveolar soft part sarcoma of the scapula,” Case Reports in Oncology, vol. 6, no. 2, pp. 356–361, 2013.

[11] R. Mannan, T. S. Bhasin, P. Kaur, M. Manjari, and K. S. Gill, “Prominent intracytoplasmic crystals in alveolar soft part sarcoma (ASPS): an aid in cytological diagnosis,” Journal of Clinical and Diagnostic Research, vol. 8, no. 2, pp. 145–146, 2014.

[12] S. Kummar, D. Allen, A. Monks et al., “Cediranib for metastatic alveolar soft part sarcoma,” Journal of Clinical Oncology, vol. 31, no. 18, pp. 2296–2302, 2013.

[13] Y. J. Cho and J. Y. Kim, “Alveolar soft part sarcoma: clinical presentation, treatment and outcome in a series of 19 patients,” Clinics in Orthopedic Surgery, vol. 6, no. 1, pp. 80–86, 2014.

[14] P. Reichardt, T. Lindner, D. Pink, P. C. Thuss-Patience, A. Kretzschmar, and B. Dörken, “Chemotherapy in alveolar soft part sarcomas. What do we know?” European Journal of Cancer, vol. 39, no. 11, pp. 1511–1516, 2003.

[15] C. A. Portera Jr., V. Ho, S. R. Patel et al., “Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution,” Cancer, vol. 91, no. 3, pp. 585–591, 2001.

[16] A. S. Pappo, D. M. Parham, A. Cain et al., “Alveolar soft part sarcoma in children and adolescents: Clinical features and outcome of 11 patients,” Medical and Pediatric Oncology, vol. 26, no. 2, pp. 81–84, 1996.

[17] Z. Chen, C. Sun, W. Sheng et al., “Alveolar soft-part sarcoma in the left forearm with cardiac metastasis: a case report and literature review,” Oncology Letters, vol. 11, no. 1, pp. 81–84, 2016.

[18] Y. Akiyama, T. Baba, Y. Ibayashi, Y. Asai, and K. Houkin, “Alveolar soft part sarcoma in brain with cardiac metastasis. A case report,” International Journal of Cardiology, vol. 114, no. 3, pp. E93–E95, 2007.

[19] T. Strecker, A. Schmid, A. Agaimy, C. Hugo, M. Weyand, and T. Zielzeinski, “Giant metastatic alveolar soft part sarcoma in the left ventricle: appearance in echocardiography, magnetic resonance imaging, and histopathology,” Clinical Cardiology, vol. 34, no. 3, p. E8, 2011.

[20] B. Campbell, J. F. Seymour, G. Wheeler, and M. Sexton, “Alveolar soft-part sarcoma: a cardiac metastasis as a rare site of relapse,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 29, no. 4, pp. 422–423, 2006.

[21] R. M. Stark, J. K. Perloff, J. H. Glick, J. W. Hirshfeld, and R. B. Devereux, “Clinical recognition and management of cardiac metastatic disease. Observations in a unique case of alveolar soft part sarcoma,” The American Journal of Medicine, vol. 63, no. 4, pp. 653–659, 1977.

[22] J. G. Lorigan, F. N. O’Keeffe, H. L. Evans, and S. Wallace, “The radiologic manifestations of alveolar soft-part sarcoma,” American Journal of Roentgenology, vol. 153, no. 2, pp. 335–339, 1989.

[23] C. D. M. Fletcher, J. A. Bridge, P. C. W. Hogendoorn, and F. Mertens, Eds., Pathology and Genetics of Tumours of Soft Tissue and Bone, vol. 5, IARC Press, Lyon, France, 2013, World Health Organization Classification of Tumors; vol 5.

[24] P. Argani, P. Lal, B. Hutchinson, M. Y. Lui, V. E. Reuter, and M. Ladanyi, “Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay,” The American Journal of Surgical Pathology, vol. 27, no. 6, pp. 750–761, 2003.